GENINCODE PLC LS -01 Total Liabilities
GENINCODE PLC LS -01 total liabilities. Based on the latest financial reports, GENINCODE PLC LS -01 (9PL) has total liabilities worth €2.25 Million EUR (≈ $2.63 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check GENINCODE PLC LS -01 (9PL) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of GENINCODE PLC LS -01 (2021–2025)
Total liabilities of GENINCODE PLC LS -01 from 2021 to 2025. This chart illustrates how GENINCODE PLC LS -01's total liabilities have evolved over time, based on quarterly financial data.
GENINCODE PLC LS -01 Competitors by Total Liabilities
The table below lists competitors of GENINCODE PLC LS -01 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GD Culture Group Limited
NASDAQ:GDC
|
USA | $1.93 Million |
|
UNIDOC HEALTH CORP.
F:L7T
|
Germany | €2.33 Million |
|
KST Beteiligungs AG
F:KSW
|
Germany | €3.01 Million |
|
Vinny Overseas Limited
NSE:VINNY
|
India | Rs388.69 Million |
|
Catalina Resources Ltd
AU:CTN
|
Australia | AU$1.60 Million |
|
Tennant Minerals Ltd
AU:TMS
|
Australia | AU$299.10K |
|
Sundaram Multi Pap Limited
NSE:SUNDARAM
|
India | Rs319.38 Million |
|
Envy Technologies Indonesia Tbk PT
JK:ENVY
|
Indonesia | Rp68.24 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down GENINCODE PLC LS -01's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see GENINCODE PLC LS -01 (9PL) total assets.
Liquidity & Leverage Metrics
GENINCODE PLC LS -01 Total Liabilities Ratios Explained
GENINCODE PLC LS -01 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 18.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.95 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GENINCODE PLC LS -01's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GENINCODE PLC LS -01 (2021–2025)
The table below shows the annual total liabilities of GENINCODE PLC LS -01 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €2.25 Million ≈ $2.63 Million |
+46.68% |
| 2024-12-31 | €1.54 Million ≈ $1.80 Million |
-46.98% |
| 2023-12-31 | €2.90 Million ≈ $3.39 Million |
-25.66% |
| 2022-12-31 | €3.90 Million ≈ $4.56 Million |
+161.19% |
| 2021-12-31 | €1.49 Million ≈ $1.74 Million |
-- |
About GENINCODE PLC LS -01
GENinCode Plc engages in the development and commercialization of clinical genetic tests for predictive analysis of risk to a patient's health based on genes in the United Kingdom, Spain, Italy, the United States, Germany, and internationally. The company offers CARDIO inCode Score, a genetic test to evaluate the risk of coronary heart disease; LIPID inCode, a genetic test for the diagnosis of fa… Read more